In conclusion, findings from this study showed that quantitative measures of ER, PR, HER2, and KI67, combined in the IHC4-score, provided more prognostic information than categorical combinations in immunohistochemistry-based subtypes of luminal-like breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.